The number of kidney failure patients in Indonesia who require dialysis treatment is 800,000, but only 105,000 are officially recorded. This discrepancy is due to the higher number of heart disease and stroke patients, which are the main focus of the government due to their higher mortality rates. However, it is important to note that the common causes of kidney failure begin with diabetes and heart disease, which then lead to complications such as kidney failure. Furthermore, the incidence of heart disease in Indonesia has been increasing year by year, with data showing that 3 out of 10 people are at risk of heart disease. This worrying trend has become even more concerning during the COVID-19 pandemic, as kidney failure patients with high comorbidity rates face serious health threats.
This issue has become the main focus of PT. Forsta Kalmedic Global, which is intensifying research on dialysis membranes by involving experts from various universities across Indonesia. The goal is to develop healthcare products related to dialysis membranes, as Indonesia is still reliant on imported products in this field.
PT. Forsta Kalmedic Global is a subsidiary of Kalbe Farma, operating as medical device manufacture with 10 certifications and licenses. On Wednesday (12/02/2025), Yvone Astri Della Sijabat, Director of PT. Forsta Kalmedic Global, along with several other representatives, visited the Faculty of Science and Technology, Universitas Airlangga (FST Unair) for Forsta University Roadshow event. The purpose of this roadshow is to initiate research collaborations aimed at developing research products in the form of medical devices, promoting joint research collaboration, and publishing together to produce data that can be developed into useful products. These products are expected to meet the market’s needs for medical devices, so that in the future, Indonesia will no longer depend on imported medical devices but will be able to produce high-quality, competitive medical devices domestically.
